SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

   Epiphen Solution 4% w/v, Oral drops

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

   Active Substance(s):
   Phenobarbital 4.0% w/v

   For a full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

   Oral drops solution.
   A clear, colourless, slightly viscous liquid.

4. CLINICAL PARTICULARS

4.1 Target species

   Dog

4.2 Indications for use, specifying the target species

   Phenobarbital is an antiepileptic agent for use in the control of epilepsy in the dog.

4.3 Contra-indications

   Not for use in pregnant animals or nursing bitches.
   Do not administer to animals with impaired hepatic function.

4.4 Special warnings for each target species

   None

4.5 Special precautions for use

   (i) Special precautions for use in animals

   Withdrawal of phenobarbital or transition to, or from, another type of antiepileptic therapy should be made gradually to avoid precipitating an increase in the frequency of seizures.
(ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental ingestion, seek medical attention immediately advising medical services of barbiturate poisoning, or show this container. Flammable, keep away from sources of ignition. Do not smoke. Wash hands after use.

4.6 Adverse reactions (frequency and seriousness)

Occasionally polyphagia, polyuria and polydipsia have been reported, but these effects are usually transitory and disappear with continued medication.

Toxicity may develop at doses over 20mg/kg/day or when serum phenobarbital levels rise above 45µg/ml.

In the light of isolated reports describing hepatotoxicity associated with combination anticonvulsant therapy, it is recommended that:-

1. Hepatic function is evaluated prior to initiation of therapy (e.g. measurement of serum bile acids).

2. Therapeutic phenobarbital serum concentrations are monitored to enable the lowest effective dose to be used. Typically concentrations of 15 - 45µg/ml are effective in controlling epilepsy.

3. Hepatic function is re-evaluated on a regular (6 to 12 month) basis.

4. Seizure activity is re-evaluated on a regular basis.

4.7 Use during pregnancy, lactation or lay

In humans, mothers receiving antiepileptic medication have a 6 to 10% incidence of significant abnormality in their offspring. Neonatal sedation and drug dependence may occur if given close to term. Phenobarbital crosses the placental barrier and small amounts are excreted in breast milk. Therefore, phenobarbital is contraindicated in pregnancy and nursing bitches.

4.8 Interaction with other medicinal products and other forms of interaction

Phenobarbital will potentially reduce therapeutic levels of a wide range of drugs due to its inducing effect on hepatic enzymes.

Phenobarbital may reduce the activity of some drugs by increasing the rate of metabolism through induction of drug-metabolising enzymes in liver microsomes.

Use of phenobarbital in conjunction with primidone is not recommended as primidone is predominantly metabolised to phenobarbital.
4.9 Amounts to be administered and administration route

The required dosage will differ to some extent between individuals and with the nature and severity of the disorder.

Dogs should be dosed orally, starting with a dose of 2.5 - 5.0 mg/kg (0.06 - 0.125ml per kg) bodyweight per day. The dose should be divided and administered twice daily using the 2ml syringe provided. 1ml contains 40mg of phenobarbital.

DOSAGE GUIDE

<table>
<thead>
<tr>
<th>Weight of dog</th>
<th>Volume of Epiphen Solution</th>
<th>Dosage range mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 - 1.5 kg</td>
<td>0.1ml</td>
<td>2.7 – 4.0</td>
</tr>
<tr>
<td>2 – 3 kg</td>
<td>0.2ml</td>
<td>2.7 – 4.0</td>
</tr>
<tr>
<td>4 – 5 kg</td>
<td>0.4ml</td>
<td>3.2 – 4.0</td>
</tr>
<tr>
<td>6 - 9 kg</td>
<td>0.7ml</td>
<td>3.1 – 4.7</td>
</tr>
<tr>
<td>10 – 15 kg</td>
<td>1.2ml</td>
<td>3.2 – 4.8</td>
</tr>
<tr>
<td>16 – 20 kg</td>
<td>1.6ml</td>
<td>3.2 – 4.0</td>
</tr>
</tbody>
</table>

Steady state serum concentrations are not reached until 1 - 2 weeks after treatment is initiated. The full effect of the medication does not appear for two weeks and doses should not be increased during this time.

If seizures are not being controlled, the dosage may be increased by 20% at a time, with associated monitoring of serum phenobarbital levels. The phenobarbital serum concentration may be checked after steady state has been achieved, and if it is less than 15µg/ml the dose may be adjusted accordingly. If seizures recur the dose may be raised up to a maximum serum concentration of 45µg/ml. High plasma concentrations may be associated with hepatotoxicity. Blood samples should be taken at the same time to allow plasma phenobarbital concentration to be determined preferably during trough levels, shortly before the next dose of phenobarbital is due.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Overdosage may result in coma, severe respiratory and cardiovascular depression, hypotension and shock leading to renal failure and death.

Following the recent ingestion of an overdose, the stomach may be emptied by lavage.

The prime objectives of management are then intensive symptomatic and supportive therapy with particular attention being paid to the maintenance of cardiovascular, respiratory and renal functions and to the maintenance of the electrolyte balance.

4.11 Withdrawal period(s)

N/A
5. PHARMACOLOGICAL PROPERTIES

The antiepileptic effects of phenobarbital are probably the result of at least two mechanisms:- Decreased monosynaptic transmission, which presumably results in reduced neuronal excitability and an increase in the motor cortex’s threshold for electrical stimulation.

After oral administration of phenobarbital to dogs, the drug is rapidly absorbed and maximal plasma concentrations are reached within 4 - 8 hours. Bioavailability is between 86% - 96%. About 45% of the plasma concentration is protein bound. Metabolism is by aromatic hydroxylation of the phenyl group in the para position, and about one third of the drug is excreted unchanged in the urine. Elimination half-lives vary considerably between individuals and range from about 40 - 90 hours.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Ethanol
Propylene glycol
Deionised water

6.2 Incompatibilities

None known

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

6.4 Special precautions for storage

Do not store above 25ºC

Protect from light.

Store in tightly closed original container

6.5 Nature and composition of immediate packaging

30 ml presentation in a carton

- amber glass vial of type II
- polyethylene syringe applicator
- medium density child proof polyethylene cap
- 2 ml polypropylene graduated syringe

A cardboard carton containing a 100 ml high density polyethylene bottle with an integral syringe adaptor insert closed with a child resistant cap. A 1.5ml polyethylene syringe barrel with graduated polystyrene plunger is also supplied.
A cardboard carton containing a 250 ml amber glass bottle closed with a child resistant cap.

Not all pack sizes are marketed

6.6 **Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused product must be destroyed in accordance with the Misuse of Drugs Regulations (2001). Any waste material should be disposed of in accordance with local requirements.

7. **MARKETING AUTHORISATION HOLDER**

Vetoquinol UK Limited
Steadings Barn
Pury Hill Business Park
Nr. Alderton
Towcester
Northamptonshire
NN12 7LS

8. **MARKETING AUTHORISATION NUMBER**

Vm 08007/4081

9. **DATE OF FIRST AUTHORISATION**

16 July 2001

10. **DATE OF REVISION OF THE TEXT**

May 2018

Approved: 02 May 2018